Drugs / SJ733
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02661373 | Mar 2016 → Mar 2018 | malaria | St. Jude Children's Research Hospital | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07430592 | Jul 2026 → Nov 2028 expected | Plasmodium vivax malaria | R. Kiplin Guy | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SJ733 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07430592 ↗ |
| Action | Inhibit | “SJ733 is an oral, novel inhibitor of Plasmodium Falciparum plasma membrane protein PFATP4.” NCT02661373 ↗ |
| Modality | Small molecule | — CHEMBL4207489 ↗ |
| Route | Oral | “It will be administered as a single, multi, or boosted oral dose.” NCT02661373 ↗ |